GlassScriptPhysician profile
Michael W Tsang
NPI 1053335117
$4,794.17
in general payments reported to CMS, 2019-2025
22 companies · $215 in 2025
The $215 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $1,103 · 2022: $30.00 · 2023: $417 · 2024: $2,736 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,090 · Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,089.61 |
| Food and Beverage | $1,278.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,444.97 | 2019-2025 | Mitraclip, Triclip |
| Edwards Lifesciences Corporation | $1,719.80 | 2023-2024 | Evoque, Sapien 3 Ultra Resilia |
| Amgen INC. | $116.11 | 2019-2024 | Repatha |
| Baxter Healthcare | $75.78 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Amarin Pharma, INC. | $57.31 | 2020 | |
| Irhythm Technologies, INC. | $40.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $40.06 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $31.48 | 2019-2023 | Camzyos |
| Bardy Diagnostics, INC. | $30.00 | 2022 | |
| Pfizer INC. | $24.94 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.65 | 2019 | |
| Biotronik INC. | $22.77 | 2023 | Biomonitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.42 | 2019 | |
| Boston Scientific Corporation | $20.49 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $18.14 | 2020 | |
| Medtronic Vascular, INC. | $15.88 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.37 | 2019 | |
| Atricure, INC. | $14.80 | 2023 | |
| Chiesi USA, INC. | $13.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tsang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.